KINE 2475 Lecture Notes - Lecture 53: Alogliptin, Agonist, Diabetes Mellitus Type 2

• School: York University
• Department: Kinesiology & Health Science
• Course: KINE 2475
• Professor: Dave Chambers

Document Summary

Type 1 diabetes insulin: rapid-acting insulin analogues (raias) - insulin aspart, glulisine & lispro allow for control over postprandial glucose b/c faster onset of action compared to short- acting. Administered 2 minutes prior to meal or 20 mins after. Long-acting insulin analogues (laias)- detemir, glargine- produce more predictable effects than intermediate-acting human insulin (nph). Laias associated w/fewer episodes of hypoglycemia, & nocturnal hypoglycemia. Insulin glargine is avalible in 100u/ml & 300u/ml. 300u/ml has longer duration of action, no peak effect & reduced hypoglycemia compared to 100. Insulin degludec has long-acting basal insulin w/duration of action of 42 hours. Intensive treatment regimens control blood sugar more effectively than conventional regimens. Reduce risk of long-term diabetic microvascular complications (retinopathy, nephrophy, neuropathy). Insulin pumps can achieve a tighter & reproducible degree of glycemic control. Intensive: basal-bolus (mdi) regimens: rapid or short-acting (bolus): aspart, glulisine or lispro taken before meals. Intermediate or long-acting (basal): degludec, detmemir, glargine - taken at supper or hs.